Compare Globus Medical Inc. Class A Common Stock (GMED) vs Gartner Inc (IT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Gartner Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Gartner Inc trades at $197.19 (market cap $12.44B). The key difference: Gartner Inc is the larger of the two by market cap, and Gartner Inc is more actively traded (818,587 versus 1,108,124). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Gartner Inc for 65 Days on average.
| GMED | IT | |
|---|---|---|
Market Cap | $10.25B | $12.44B |
Volume | 1,108,124 | 818,587 |
Sector | Health | Technology |
52-Week High | $96.82 | $258.17 |
52-Week Low | $58.33 | $125.68 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $9.76B | $14.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Gartner Inc. (IT) trades at $195.77, up 0.86% on the day, with a bullish technical signal and strong profitability metrics including a 69.63% gross margin and 113.58% ROE. Recent earnings beats and positive news flow around AI advisory demand support the stock, though net cash flow turned negative in 2025. The current price sits above the consensus target of $178.14, indicating potential overvaluation concerns among analysts.
Outlook remains positive due to robust contract value growth and AI-driven demand, but risks include volatile cash flows, high P/B ratio of 160.06, and a shareholder investigation. Investor sentiment is mixed with 55.55% hold ratings, suggesting cautious optimism amid execution risks and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →
